Awakn Life Sciences (TSE:AWKN) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Awakn Life Sciences has partnered with the University of Nottingham to conduct preclinical trials on a new chemical entity aimed at enhancing mental health treatments. The study, led by Dr. Madeleine King, focuses on the potential of aminoindane to improve social cognition and behaviors, particularly for PTSD. This collaboration marks a significant step in Awakn’s mission to develop innovative therapies for mental health disorders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue